İçeriğe geç
akaturk Akademik ölçüm
Giriş Kayıt

Akademisyen

ERKAN KAYIKÇIOĞLU

DOÇENT

İSTİNYE ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Tıbbi Onkoloji (İç Hastalıkları)

Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.

  • Makale 26
  • Proje 0
  • Kitap 5
  • Bildiri 10
  • Patent 0
  • Sanatsal 0
Scopus (SJR) Q1 1 Q2 5 Q3 4 Q4 5
WoS (JCR) Q1 0 Q2 5 Q3 5 Q4 2
TR Index 7 makale

Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.

Üst %1 makale 0
Üst %10 makale 4
Ort. yüzdelik 57.2%
Üst %1 payı 0.0%
Üst %10 payı 18.2%

Makaleler

YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.

Dizin filtreleri

Toplam 26 yayın

Scopus (SJR)
Q1 1 Q2 5 Q3 4 Q4 5
WoS (JCR)
Q1 0 Q2 5 Q3 5 Q4 2
TR Index
7 makale

Makale listesi

  1. 2025 Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study Journal of Chemotherapy DOI 10.1080/1120009X.2024.2330835 YÖKSİS SJR Q3 JCR Q3 OpenAlex 87.7%
  2. 2025 Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study Journal of Chemotherapy DOI 10.1080/1120009X.2024.2366683 YÖKSİS SJR Q3 JCR Q3 OpenAlex 50.8%
  3. 2025 Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study Clinical Breast Cancer DOI 10.1016/j.clbc.2025.03.003 YÖKSİS SJR Q2 JCR Q3 OpenAlex 88.9%
  4. 2025 HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy Turkish Journal of Clinics and Laboratory DOI 10.18663/tjcl.1639022 YÖKSİS TR Index OpenAlex 69.4%
  5. 2024 The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY DOI 10.1007/s10147-023-02460-5 YÖKSİS SJR Q1 JCR Q2 OpenAlex 87.5%
  6. 2023 Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy BMC CANCER DOI 10.1186/s12885-023-10662-3 YÖKSİS SJR Q2 JCR Q2
  7. 2023 Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cance future medicine DOI 10.2217/fon-2022-1287 YÖKSİS SJR Q3 OpenAlex üst %10 OpenAlex 95.3%
  8. 2023 Prognostic value of claudin 18.2 expression in gastric adenocarcinoma World Journal of Gastrointestinal Oncology DOI 10.4251/wjgo.v15.i2.343 YÖKSİS SJR Q2 JCR Q3 OpenAlex üst %10 OpenAlex 90.2%
  9. 2023 The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes Medicine DOI 10.1097/MD.0000000000032882 YÖKSİS SJR Q3 JCR Q2 OpenAlex 84.2%
  10. 2023 The Efficacy of Pazopanib in Ewing Sarcoma Chronicles of Precision Medical Researchers DOI 10.5281/zenodo.7709543 YÖKSİS OpenAlex 4.9%
  11. 2023 A Novel Prognostic Index for Metastatic Colon Cancer: The Prognostic Immune Nutritional Index Cureus, Inc. DOI 10.7759/cureus.33808 YÖKSİS JCR Q3 OpenAlex 85.6%
  12. 2023 Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy BMC Cancer DOI 10.1186/s12885-023-10609-8. YÖKSİS SJR Q2 JCR Q2 OpenAlex üst %10 OpenAlex 94.2%
  13. 2022 Prognostic value of clinicopathological characteristic of patients with Malign Mesothelioma at Mediternean region of Turkey Cagdas Tip Dergisi: Journal of Contemporary Medicine DOI 10.16899/jcm.1173730 YÖKSİS OpenAlex 22.6%
  14. 2022 The Pan-Immune-Inflammation Value Predicts the Survival of Patients with ER-positive, HER-2-Negative Metastatic Breast Cancer Treated with CDK4/6 inhibitors Chronicles of Precision Medical Researchers DOI 10.5281/zenodo.7195780 YÖKSİS OpenAlex 50.5%
  15. 2022 The prognostic immune nutritional index is a predictive biomarker in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide The Injector DOI 10.5281/zenodo.7331456 YÖKSİS OpenAlex 22.1%
  16. 2022 Isparta Burdur Yöresindeki Kolon Kanseri Hastalarının Demografik ve Klinik Özellikleri Medical Journal of Suleyman Demirel University DOI 10.17343/sdutfd.1104209 YÖKSİS OpenAlex 13.1%
  17. 2022 SELÇUK ÜNİVERSİTESİ MERAM TIP FAKÜLTESİ SAĞLIK ÇALIŞANLARINDA FONKSİYONEL GASTROİNTESTİNAL BOZUKLUKLARIN ROMA III KRİTERLERİ EŞLİĞİNDE SIKLIĞI VE BİRLİKTELİĞİNİN BELİRLENMESİ Turkish Journal of Clinics and Laboratory DOI 10.18663/tjcl.788057 YÖKSİS TR Index OpenAlex 24.8%
  18. 2018 Acute pancreatitis linked to bevacizumab: A case report Journal of Oncological Sciences (JOS) DOI 10.1016/j.jons.2018.03.004 YÖKSİS SJR Q4 OpenAlex 63.0%
  19. 2018 A challenging palliation via novel therapeutic approach for unusual presenting with gingival metastasis from renal cell carcinoma relapsed eight years after nephrectomy The European Research Journal DOI 10.18621/eurj.348318 YÖKSİS TR Index OpenAlex 44.0%
  20. 2017 An extremely rare neoplasm, histiocytic sarcoma: A report of two cases with an aggressive clinical course Journal of Oncological Sciences (JOS) DOI 10.1016/j.jons.2017.05.007 YÖKSİS SJR Q4 OpenAlex 62.5%

Akademisyenlere dön